Home Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome
Article
Licensed
Unlicensed Requires Authentication

Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome

  • Shulan Zhang , Ziyan Wu , Wen Zhang , Jiuliang Zhao , Gary L. Norman , Xiaofeng Zeng , Fengchun Zhang and Yongzhe Li EMAIL logo
Published/Copyright: March 21, 2018

Abstract

Background:

Increasing evidence has highlighted the role of non-criteria antiphospholipid antibodies (aPLs) as important supplements to the current criteria aPLs for the diagnosis of antiphospholipid syndrome (APS). In this retrospective study, we evaluated the clinical relevance of antibodies to phosphatidylserine/prothrombin (aPS/PT) in Chinese patients with APS.

Methods:

A total of 441 subjects were tested, including 101 patients with primary APS (PAPS), 140 patients with secondary APS (SAPS), 161 disease controls (DCs) and 39 healthy controls (HCs). Serum IgG/IgM aPS/PT was determined by ELISA.

Results:

The levels of IgG/IgM aPS/PT were significantly increased in patients with APS compared with DCs and HCs. IgG and IgM aPS/PT were present in 29.7% and 54.5% of PAPS, and 42.1% and 53.6% of SAPS, respectively. For diagnosis of APS, IgG aCL exhibited the highest positive likelihood ratio (LR+) of 21.60, followed by LA (13.84), IgG aβ2GP1 (9.19) and IgG aPS/PT (8.49). aPS/PT was detected in 13.3% of seronegative PAPS patients and 31.3% of seronegative SAPS patients. LA exhibited the highest OR of 3.64 in identifying patients with thrombosis, followed by IgG aCL (OR, 2.63), IgG aPS/PT (OR, 2.55) and IgG aβ2GP1 (OR, 2.33). LA and IgG aCL were correlated with both arterial and venous thrombosis, whereas IgG aPS/PT and IgG aβ2GP1 correlated with venous or arterial thrombosis, respectively.

Conclusions:

Our findings suggest that the inclusion of IgG/IgM aPS/PT may enhance the diagnostic performance for APS, especially in those in whom APS is highly suspected, but conventional aPLs are repeatedly negative. In addition, IgG aPS/PT may contribute to identify patients at risk of thrombosis.

Acknowledgments

We thank all the people from the Department of Rheumatology and Clinical Immunology, PUMCH, for their assistance during this study.

  1. Author contributions: SZ, FZ and YL designed the study. SZ, ZW, WZ, JZ, XZ, GLN and YL performed the experiments and analyzed the data. SZ, GLN, FZ and YL wrote the manuscript. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: This work was supported in part by the National Natural Science Foundation of China, Funder ID: 10.13039/501100001809; grant nos. 81373188, 81671618/81172857 (to YL) and 81771661 (to SZ); Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative Medicine (CAMS-I2M) grant no. 2017-I2M-3-001 (to SZ and YL); and The National Key Research and Development Program of China grant no. 2016YFC0903900 (to YL).

  3. Employment or leadership: Gary L. Norman is an employee of Inova Diagnostics.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010;376:1498–509.10.1016/S0140-6736(10)60709-XSearch in Google Scholar

2. Chaturvedi S, McCrae KR. Diagnosis and management of the antiphospholipid syndrome. Blood Rev 2017;31:406–17.10.1016/j.blre.2017.07.006Search in Google Scholar PubMed PubMed Central

3. Manukyan D, Rossmann H, Schulz A, Zeller T, Pfeiffer N, Binder H, et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med 2016;54:1663–70.10.1515/cclm-2016-0014Search in Google Scholar PubMed

4. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.10.1111/j.1538-7836.2006.01753.xSearch in Google Scholar PubMed

5. Rodriguez-Garcia V, Ioannou Y, Fernandez-Nebro A, Isenberg DA, Giles IP. Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford) 2015;54:2042–50.10.1093/rheumatology/kev226Search in Google Scholar PubMed

6. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717–23.10.1182/blood-2002-11-3334Search in Google Scholar PubMed

7. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, et al. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001;113:621–9.10.1046/j.1365-2141.2001.02755.xSearch in Google Scholar PubMed

8. Haj-Yahia S, Sherer Y, Blank M, Kaetsu H, Smolinsky A, Shoenfeld Y. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus 2003;12:364–9.10.1191/0961203303lu370oaSearch in Google Scholar PubMed

9. Vega-Ostertag M, Liu X, Kwan-Ki H, Chen P, Pierangeli S. A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 2006;135:214–9.10.1111/j.1365-2141.2006.06283.xSearch in Google Scholar PubMed

10. Yang YH, Chang CJ, Chuang YH, Hsu HY, Chen PP, Chiang BL. Identification of anti-prothrombin antibodies in the anti-phospholipid syndrome that display the prothrombinase activity. Rheumatology (Oxford) 2010;49:34–42.10.1093/rheumatology/kep328Search in Google Scholar PubMed

11. Chighizola CB, Raschi E, Banzato A, Borghi MO, Pengo V, Meroni PL. The challenges of lupus anticoagulants. Expert Rev Hematol 2016;9:389–400.10.1586/17474086.2016.1140034Search in Google Scholar PubMed

12. Pregnolato F, Chighizola CB, Encabo S, Shums Z, Norman GL, Tripodi A, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res 2013;56:432–8.10.1007/s12026-013-8421-zSearch in Google Scholar PubMed

13. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 2014;111:354–64.10.1160/TH13-06-0509Search in Google Scholar PubMed

14. Zhang S, Wu Z, Li J, Li P, Chen S, Wen X, et al. Clinical performance of antibodies to prothrombin and thrombin in Chinese patients with antiphospholipid syndrome: potential interest in discriminating patients with thrombotic events and non-thrombotic events. Rheumatol Int 2017;37:579–84.10.1007/s00296-016-3594-0Search in Google Scholar PubMed

15. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003;48:886–95.10.1002/art.10831Search in Google Scholar PubMed

16. Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 2005;93:289–97.10.1160/TH04-06-0382Search in Google Scholar PubMed

17. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014;13:917–30.10.1016/j.autrev.2014.05.001Search in Google Scholar PubMed

18. Hoxha A, Ruffatti A, Mattia E, Meneghel L, Tonello M, Salvan E, et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med 2015;53:1265–70.10.1515/cclm-2014-1129Search in Google Scholar PubMed

19. Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL, et al. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 2014;12:792–5.10.1111/jth.12537Search in Google Scholar PubMed

20. Institute CaLS. User verification of performance for precision and trueness; approved guidelines. 2nd ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2005Search in Google Scholar

21. Sciascia S, Khamashta MA, Bertolaccini ML. New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep 2014;16:415.10.1007/s11926-014-0415-xSearch in Google Scholar PubMed

22. Galli M, Beretta G, Daldossi M, Bevers EM, Barbui T. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost 1997;77:486–91.10.1055/s-0038-1655994Search in Google Scholar

23. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982–93.10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2Search in Google Scholar

24. Egerer K, Roggenbuck D, Buttner T, Lehmann B, Kohn A, von Landenberg P, et al. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res Ther 2011;13:R118.10.1186/ar3421Search in Google Scholar

25. Roggenbuck D, Egerer K, von Landenberg P, Hiemann R, Feist E, Burmester GR, et al. Antiphospholipid antibody profiling: time for a new technical approach? Autoimmun Rev 2012;11:821–6.10.1016/j.autrev.2012.02.016Search in Google Scholar

26. Hoxha A, Mattia E, Tonello M, Grava C, Pengo V, Ruffatti A. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med 2017;55:890–8.10.1515/cclm-2016-0638Search in Google Scholar

27. Vlagea A, Gil A, Cuesta MV, Arribas F, Diez J, Lavilla P, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost 2013;19:289–96.10.1177/1076029612437578Search in Google Scholar

28. Zohoury N, Bertolaccini ML, Rodriguez-Garcia JL, Shums Z, Ateka-Barrutia O, Sorice M, et al. Closing the serological gap in the antiphospholipid syndrome: the value of “Non-criteria” antiphospholipid antibodies. J Rheumatol 2017;44:1597–602.10.3899/jrheum.170044Search in Google Scholar

29. Nojima J, Motoki Y, Aoki N, Tsuneoka H, Ichihara K. A novel ELISA system for simultaneous detection of six subclasses of anti-phospholipid antibodies for prediction of thrombotic complications among SLE patients. Thromb Res 2014;133:1135–40.10.1016/j.thromres.2014.03.032Search in Google Scholar

30. Zigon P, Cucnik S, Ambrozic A, Kveder T, Semrl SS, Rozman B, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol 2013;2013:724592.10.1155/2013/724592Search in Google Scholar

31. Sugiura-Ogasawara M, Atsumi T, Ozaki Y, Koike T, Suzumori K. Phosphatidylserine-dependent antiprothrombin antibodies are not useful markers for high-risk women with recurrent miscarriages. Fertil Steril 2004;82:1440–2.10.1016/j.fertnstert.2004.06.034Search in Google Scholar

32. Alijotas-Reig J, Ferrer-Oliveras R, Rodrigo-Anoro MJ, Farran-Codina I, Cabero-Roura L, Vilardell-Tarres M. Anti-beta(2)-glycoprotein-I and anti-phosphatidylserine antibodies in women with spontaneous pregnancy loss. Fertil Steril 2010;93:2330–6.10.1016/j.fertnstert.2009.01.089Search in Google Scholar PubMed

33. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006;33:2214–21.Search in Google Scholar

34. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997;78:1008–14.10.1055/s-0038-1657678Search in Google Scholar

35. Peterson LK, Willis R, Harris EN, Branch WD, Tebo AE. Antibodies to phosphatidylserine/prothrombin complex in antiphospholipid syndrome: analytical and clinical perspectives. Adv Clin Chem 2016;73:1–28.10.1016/bs.acc.2015.10.003Search in Google Scholar PubMed

Received: 2017-9-7
Accepted: 2017-11-27
Published Online: 2018-3-21
Published in Print: 2018-5-24

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Developments in laboratory testing for autoimmune diseases
  4. Reviews
  5. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors
  6. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection
  7. Mini Reviews
  8. Insulin autoimmune syndrome (Hirata’s disease) in an Italian patient: a case report and review of the literature
  9. The natural history of autoimmune Addison’s disease with a non-classical presentation: a case report and review of literature
  10. Opinion Paper
  11. Quality and future of clinical laboratories: the Vico’s whole cyclical theory of the recurring cycles
  12. General Clinical Chemistry and Laboratory Medicine
  13. Screening for connective tissue disease-associated antibodies by automated immunoassay
  14. Analysis of anti-ganglioside antibodies by a line immunoassay in patients with chronic-inflammatory demyelinating polyneuropathies (CIDP)
  15. Detection of autoantibodies to the p200-epitope of SSA/Ro52 antigen. A comparison of two laboratory assays
  16. A new ELISA for autoantibodies to steroid 21-hydroxylase
  17. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome
  18. Borderline positive antineutrophil cytoplasmic antibodies (ANCA)-PR3/MPO detection in a large cohort tertiary center: lessons learnt from a real-life experience
  19. Reference Values and Biological Variations
  20. Short- and medium-term biological variation estimates of red blood cell and reticulocyte parameters in healthy subjects
  21. Pediatric reference intervals for 1,25-dihydroxyvitamin D using the DiaSorin LIAISON XL assay in the healthy CALIPER cohort
  22. Reference intervals for biochemical, haemostatic and haematological parameters in healthy Chinese women during early and late pregnancy
  23. Cancer Diagnostics
  24. Use of circulating tumor cells in prospective clinical trials for NSCLC patients – standardization of the pre-analytical conditions
  25. High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease
  26. Infectious Diseases
  27. Diagnosis of acute pediatric appendicitis from children with inflammatory diseases by combination of metabolic markers and inflammatory response variables
  28. Letters to the Editor
  29. Repeat requesting on hemolysed plasma potassium requests
  30. A case report of insulin autoimmune syndrome in a Central European individual
  31. Traceability of alkaline phosphatase measurement may also vary considerably using the same analytical system: the case of Abbott Architect
  32. Abiraterone acetate: a potential source of interference in testosterone assays
  33. Falsely elevated plasma testosterone concentrations in neonates: importance of LC-MS/MS measurements
  34. Rational approach to the primary evaluation of thyroid disease in paediatrics. Full thyroid profile vs. thyroid-stimulating hormone and free thyroxine only
  35. Diagnostic performance of the N-terminal pro-brain natriuretic peptide to detect an increased left atrial pressure in patients with persistent atrial fibrillation
  36. Is the DNA of placental origin packaged in exosomes isolated from plasma and serum of pregnant women?
  37. Gamma heavy chain disease evolving during the progression of chronic lymphocytic leukemia
  38. Congress Abstracts
  39. ISMD2018 Twelfth International Symposium on Molecular Diagnostics
Downloaded on 19.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2017-0811/html
Scroll to top button